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Abstract
The global pandemic of coronavirus (CoV) d0isease 2019 (COVID-19), caused by severe acute respiratory 
syndrome CoV (SARS-CoV 2), has been a challenging event for every individual. It is known that COVID-
19 may exhibit a vast range of symptoms ranging from mild to severe. Acute respiratory distress syndrome 
(ARDS) and multiple organ failure are the most common causes of death in COVID-19 cases [3]. Accumulating 
evidence shows that T-helper type (Th-1) inflammation cascade plays a major role in COVID-19 pathogenesis. 
It is proposed that aberrant immune reaction, or known as cytokine storm, is one of the main causals of ARDS 
in COVID-19 case, while dupilumab, the first Food and Drug Administration-approved immunomodulatory 
treatment for atopic dermatitis, is known for its effectiveness in suppressing the Th-2 inflammation pathway. 
It is postulated that both types of inflammation can cross-regulate each other. Therefore, some may believe 
that the regression of Th-2 cascade may upregulate the Th-1 cascade, leading to an exaggerated cytokine 
storm. This hypothesis leads to the uncertainty of the safety of continuing this modality during the pandemic.
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Introduction
Atopic dermatitis (AD) can be deemed as one 
of the most common non-communicable dermatological 
ailments. It affects approximately 20% of children 
and 2–8% adults in most nations of the world [8]. An 
international study shows that the figure has increased 
two-or three-fold within three decades in the developed 
countries. Therefore, it is predicted that the number will 
always accumulate, and this also shows that AD is a 
global health problem both in developing and developed 
nations [9].
Both personal and social aspects are greatly 
influenced by uncontrollable AD. For instance, the 
social stigma of visible skin efflorescence may affect 
individual’s self-confidence, and debilitating itch 
might lower one’s quality of life [10], [11]. Dupilumab, 
as the first Food and Drug Administration-approved 
biologic treatment, has been proven effective and has 
significantly improved quality of life. Some concerns 
about the safety of the utilization of dupilumab have been 
raised during coronavirus (CoV) disease (COVID)-19 
pandemic. Some may fear that dupilumab may increase 
the susceptibility of acquiring COVID-19 or worsen the 
condition. However, it is also not recommended to 
discontinue dupilumab because of the chronic nature of 
AD and the unknown period of this pandemic [12].
In this article, the literature reviews of both 
clinical and immunology aspects of dupilumab in AD and 
COVID-19 have been explored. The aim is to provide 
the latest reference about dupilumab in AD patients and 
COVID-19. Thus, it can assist physicians in generating 
the best clinical judgment in a practice setting.
A Glance of AD
What is AD?
AD is defined as a chronic inflammatory 
skin disorder, with one of the major hallmarks of 
extremely pruritic, and it is very common to be found 
during infancy and childhood period [13]. It is crucial 
to bear in mind that the diagnosis of AD includes an 
array of major and minor features. There is no single 
feature that can represent AD itself nor a diagnostic 
assessment [14], [15] (Table 1). Many guidelines and 
suggestions have been published to aid clinicians in 
establishing the diagnosis. However, it is implied by 
Tada [16] that mostly adopted guideline for diagnosing 
both in practice settings and clinical trials is the 
revised Hanifin and Rajla criteria. The diagnostic can 
be established when at least three major features and 
three minor features are noted [17].
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AD is a very complicated and debilitating condition, 
and individuals may suffer from both physical and mental 
issues due to uncontrollable AD. Literature shows that AD 
is significantly affecting all aspects of the quality of life of 
patients and their families [11], [18], [19] (Figures 1 and 2).
Pathogenesis
The pathogenesis of AD is subsequently complex 
and is not fully elucidated until now. Many theories are 
proposed and postulated; however, it is widely agreed that 
AD is orchestrated from defective skin integrity, particular 
genes, and dramatic response of the immune system 
against exacerbating factors [14], [21], [22].
In general, it is found that AD individuals’ skin 
lacks essential genes that are needed to form a perfect skin 
barrier. For instance, some individuals may have filaggrin 
mutation; filaggrin is a gene that encodes essential proteins 
in building the epithelial barrier and ceramide, a lipid 
substance that plays an important role in retaining water 
permeability barrier function [22], [23] The lack of these 
two major materials leads to excessive trans-epidermal 
water loss, resulting in pH alteration and skin dryness. 
In addition, an antimicrobial peptide called cathelicidin, 
which is one of the very first layers of immune barrier, is 
also found to be depleted in most AD patients. [10]. Thus, 
exacerbating environmental stimuli such as aeroallergens, 
irritating chemicals, and pathogens are easier to penetrate 
the skin, initiating inflammation [14], [22], [24].
Th-2 type cells are widely accepted to 
be associated with both acute and chronic AD 
course [10], [14], [15]. However, Fujii [25] believes that 
either in acute and chronic lesion, there might be a 
switch from Th2 to Th1 activity.
In the acute event, interleukin (IL)-4, IL-5, 
IL-13, IL-25, and IL-33 levels increase [15]. Especially, 
in the early lesion of AD, it is shown that IL-4 and 
IL-13 dominate the inflammatory cascade [14], [15]. 
Meanwhile, in chronic AD, IL-31 has recently been 
discovered to be overly expressed and linked to the 
severity of the course.
On the other hand, it is also found that IL-4, 
IL-13, and IL-33 might downregulate the filaggrin, and 
thus, it is like a loophole of the immune system and 
defective skin barrier cascades [26].
Management
Overview
In general, many findings agree that the aim of 
the treatment of AD must be focused on inflammation 
cessation by repairing the skin barrier and reducing 
the itch. The importance of education about the nature 
of the ailment, skin hydration, pharmacological regime, 
identification, and elimination of flare causal factors is 
often highlighted in virtually all guidelines [10], [14], [27]. 
Therefore, holistic and multi-faceted approaches are 
needed to manage this ailment. [8], [10], [28]. The 
Japanese guideline for AD believes that the management 
of AD must be based on three fundamental aspects. First 
is the investigation and countermeasures of the causal 
and exacerbating elements. Second is the repairment if 
the skin defect (skincare). Last is pharmacotherapy [28]. 
Similarly, the European Consensus Guidelines’ treatment 
option is quite similar to most guidelines and literature, 
aside from its agreement to divide the management into 
four phases: Baseline, mild, moderate, and severe [8]. 
The phases depend on the SCORing AD (SCORAD) 
(Appendix 1). SCORAD is one of the tools that can be 
used in assessing the extent and severity of AD. Less 
than SCORAD 25 is defined as mild, 25–50 as moderate, 
and more than 50 as severe. It is also suggested that in 
each phase, adding additional medication and antiseptic 
or antibiotic may be beneficial in treating superinfection.
A Brief Review of Dupilumab
Dupilumab is a human analogue monoclonal 
antibody that blocks IL-4 and IL-13 pathways by binding 
a shared α-subunit of IL-4 and IL-13, both of which 
are the major cytokines for Th-2 inflammation in AD 
[4], [29], [30].
Some experimental research demonstrated 
that early treatment with IL-4 and IL-3 blocking agents 
will dampen the responses to IFN and IL -17. In brief, 
when the early lesion of AD is exposed to IL-4 and 
IL-13, long-lasting persistent effects are doable [31]. 
Therefore, not only will dupilumab decrease the flare but 
it may also prevent the course of recalcitrant AD in the 
future. Dupilumab can be used either as monotherapy 
or combination therapy. Studies of dupilumab in 4 weeks 
and 12 weeks as monotherapy and as a combination 
with topical glucocorticoid in moderate-severe AD show 
significant improvement [5]. Not only were skin lesions 
improved but the severity of itch also rapidly decreased, 
allowing individuals to have a better quality of life. 
These results were also supported by a separate study, 
where Eczema Area and Severity Index score and peak 
pruritus Numerical Rating Score were reported to be 
significantly improved by the end of week 16th [32]. In 
terms of adverse effects, both placebo and intervention 
groups were almost equal [5], [32]. However, in a two 
phase 3 trial, it is also observed that nasopharyngitis 
was the second most common adverse effect after 
infection and infestation in the dupilumab groups [32]. A 
similar result is also discovered in a study of dupilumab 
and asthmatic patients [33].
 Kosasih. The Use of Dupilumab in Atopic Dermatitis During COVID-19
Open Access Maced J Med Sci. 2020 Nov 05; 8(T1):399-407. 401
COVID-19
What is COVID-19?
History
In December 2019, several pneumonia-like 
cases with unknown etiology were reported in Wuhan, 
China. This disease has started with suggestive symptoms 
of progressive respiratory infection, with some patients 
developing acute respiratory distress syndrome (ARDS), 
acute respiratory failure, and other life-threatening 
complications [34]. A novel beta-CoV was discovered 
later in January 2020 to be the culprit. International Virus 
Classification Commission named the virus as Severe 
Acute Respiratory Syndrome-CoV 2 (SARS-CoV 2), while 
the World Health Organization (WHO) officially named 
the disease as COVID-19 in the next month [1], [35]. In 
March 2020, the WHO asserted that this disease is a 
global emergency, affecting every aspect of life, and thus, 
declared COVID-19 as a pandemic [36] (Figure 3).
Incubation and Clinical Characteristic
Data show that symptoms of COVID-19 
usually appear after an incubation period of 5.1–12 
days [37]. Fever, dry cough, and fatigue are the most 
common symptoms. However, other symptoms such as 
headache, hemoptysis, and gastrointestinal symptoms 
such as diarrhea and vomiting are likely to be exhibited 
as well. In addition, dyspnea is found to be developed 
in more than half of the patients [1], [38], [39]. A recent 
study also discovered that olfactory dysfunction such 
as anosmia and hyposmia was found prominently in 
COVID-19 patients [40]. However, COVID-19 can still 
yield in a person without showing any symptom, which 
makes this ailment easily transmitted.
Route of Transmission
Human-to-human transmission is feasible due 
to respiratory fomites or droplets. It is also suggested 
that direct and non-direct contacts through mucous 
membrane of eyes, nose, mouth, and skin are another 
potential routes of transmission [39], [41]. However, 
a recent study discovered that aerosol transmission 
is highly plausible through smaller droplets or droplet 
nuclei. Therefore, proper inter-personal distancing and 
usage of mask are very essential to control the spread 
of infection [42], [43]. Due to a recent study that shows 
COVID-19 cases with enteric symptoms, it is also 
suggested that the digestive tract might be another 
possible route of transmission [44].
An article also suggests that percutaneous 
transmission is possible due to the high expression of 
Angiotensin-Converting Enzyme-2 (ACE2) in the skin 
tissue cells [45]. ACE-2 is known to facilitate the entry 
of the virus (further explanation will be explained in the 
next chapter). However, a thorough study is still needed 
to elucidate this hypothesis.
Pathogenesis
Virus structure
CoVs are enveloped with single-stranded, 
positive-strand RNA genome (26-32kb in weight) 
which comes from Coronaviridae family. There are four 
genera of CoVs; α, β, γ, δ, and COVID-19 belongs to the 
beta-CoV genus. Within beta genus itself, there are four 
lineages (A, B, C, and D) [3], [46].
The appearance of the virus is a rough, 
spherical and has prominent club-shaped elongations 
which contain its spike protein. This novel CoV 
has shown 88% similarity to bat-related SARS-like 
CoVs’ sequence (bat-SL-CoVZC45 and bat-SL-
CoVZXC21), and approximately 50% identical to 
Middle East Respiratory Syndrome CoVs’ sequence. 
Due to its similar structure, the pathogenesis of 
SARS-CoV 2 can be postulated. However, the 
complete pathogenesis of COVID-19 has not been 
fully elucidated [47].
Table 1: Major and minor features. Adapted from Goldsmith 
et al. and Correale et al. [14], [20]
Major features
1. Pruritus
2. Recurrent or relapse course of dermatitis
3.  Typical lesion (Facial and/or extensor rashes in infants and young children, and 
flexural lichenification in older children and adults)
4. Family history of atopic diatheses (asthma, allergic rhinitis, and atopic dermatitis)
Minor Features
1. Xerosis
2. Ichthyosis/palmar hyperlinearity, and keratosis pilaris
3. Immediate (type I) skin test reaction
4. Elevated IgE level
5. Early age of onset
6.  Tendency toward cutaneous infections (especially staph. aureus and herpes 
simplex), impaired cell- mediated immunity
7. Tendency toward non-specific hand or foot dermatitis 
8. Nipple eczema
9. Cheilitis
10. Recurrent conjunctivitis
11. Dennie-Morgan infraorbital fold
12. Keratoconus
13. Anterior subcapsular cataracts
14. Orbital darkening
15. Facial pallor, and facial erythema
16. Pityriasis alba
17. Anterior neck folds
18. Itch when sweating
19. Intolerance to wool and lipid solvents
20. Perifollicular accentuation
21. Food intolerance
22. Relaps influenced by environmental and emotional factor
23. White dermographism, delayed blanch
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Narrative Review Article
402 https://www.id-press.eu/mjms/index
Figure 1: Management scheme of AD in adults. Adapted from Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-
Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur 
Acad Dermatol Venereol. 2018 May;32(5):657–82
Host Entrance and Immune Response
SARS-CoV 2 can enter the host cells by 
direct membrane fusion. First, the envelope spike 
glycoprotein will bind to the host cellular receptor, 
facilitated by ACE2 [48]. After entering the cell, the virus 
RNA genome will be released to the cytoplasm and 
then commenced to the replication phase [49].
Subsequently, after the virus has successfully 
hijacked the cells, its antigen will be presented to the 
antigen presentation cells. Antigen presentation will 
evoke host immune response which is both humoral 
and cellular immunity. T cells and B cells play a major 
role as the immune mediators in this event [35].
Since COVID-19 is caused by a virus, similar 
to any viral infection, the innate immune pathway is 
the first line of defense. However, a further aberrant 
and disarrayed immune response might damage the 
immune systems, leading to fatality [3], [50]. This event is 
often known as a cytokine storm. Several studies report 
that ARDS is the main cause of mortality of COVID-19 
patients, and ARDS is one of the results of the cytokine 
storm [3], [51], [52]. This dramatic cytokines response 
makes COVID-19 difficult to manage and threaten lives.
T-helper type 1 (Th-1) cascade plays an 
essential role in COVID-19 infection. It is observed that 
cytokines that generate Th-1 pathway such as IL-1B, 
IFN-γ, IP-10, and monocyte chemoattractant protein 1 
rise [51]. This hypothesis is also supported by several 
studies and reports discovering highly expressed 
Th-1 related cytokines in many COVID-19 patients. 
For instance, a study by Huang et al. revealed that 
levels of IL-7, IL-8, IL-9, IL-10, fibroblast growth factor, 
granulocyte-colony stimulating factor, granulocyte-
macrophage colony-stimulating factor, MIP-1A,MIP1-B, 
platelet-derived growth factor, tumor necrosis factor 
(TNF)α, and VEGF surge in both ICU and non-ICU 
required COVID-19 patients compared to healthy 
individuals [51].
An analyzing case study in China also saw a 
high expression of IL-10, IL-6, and TNF-α in severe 
cases compared to moderate cases [53]. An identical 
result is also found in a study of assessment of 
laboratory data reporting that IL-6 level significantly 
rises in severe cases compared to mild cases [54]. A 
multicenter study also supports previous data, in which 
it is observed that IL-6 was found higher in mortality 
cases than successful cases [55].
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Figure 3: Structure of SARS-CoV 2. Adapted from https://
microbeonline.com/sars-cov-2-properties-transmission
Discussion
Dupilumab during COVID-19 era
It is understandable that COVID-19 alters the 
nature of AD management with dupilumab. Some AD 
patients may abruptly cease the treatment or refuse to 
take it routinely. Some cases may be caused due to 
the difficulty for accessing dermatology practices that 
are closed during lockdown or the fear of contracting 
COVID-19 from clinic visit [56]. Others may have 
concerns about the effect of dupilumab therapy and 
susceptibility of acquiring COVID-19.
Even though there are some letters of 
statement about the usage of immunomodulators usage 
in dermatology cases during COVID-19 [57], [58], 
more sources that provide information about the safety 
of biologic treatment during the COVID-19 outbreak 
are needed [59]. Even though dupilumab is not an 
immunosuppressant nor steroid that might reduce the 
immune systems, it is postulated that immunomodulators 
may affect the balance of the immune system [6]. The 
Th1/Th2 immune balance has been studied for decades. 
However, it is ultimately complex and has not been fully 
elucidated until now. It is believed that the integration 
of the immune system is achieved by cell-to-cell 
communication, facilitated by cytokines. Therefore, it can 
modulate those cells to become more active (upregulate) 
or less active (downregulate) [7]. It is hypothesized that 
suppression of Th-2 polarized cytokines may upregulate 
the Th-1 cascade activity. For instance, IL-10 is known to 
release from the Th-2 pathway, and it can downregulate 
Th-1 production [6]. This hypothesis is also supported 
by a study in autoimmune disease, stating that Th-1 and 
Th-2 inflammations work to antagonize each other. This 
may be achieved either by inhibiting the production of 
the other cell type or by hindering each other effector 
function. For instance, abundant expression of IL-3 or 
IL-6 may block the generation of Th-1 cells from naive 
T cells [60].
Figure 2: Management scheme of AD in children. Adapted from Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-
Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur 
Acad Dermatol Venereol. 2018 May;32(5):657–82
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In other words, it is plausible that the production 
of Th-1 polarized cytokines is upregulated due to the 
decreased Th-2 activity, resulting from the lower expression 
of IL-4 and IL-13, blocked by dupilumab. This may worsen 
or increase the risk of aberrant cytokine storm in COVID-19 
patients. However, a study disputes that dupilumab affects 
Th-1 activity. It is shown that no elevation of Th-1/IFN-g-
related gene expression was observed in AD patients with 
dupilumab [61]. Moreover, a hypothesis is also proposed 
that dupilumab might give AD patients more protection 
from COVID-19 infection. It is known that expression 
of IL-6, one of the infamous cytokines that play role in 
cytokine storm, is depended on endogenous production of 
IL-4, which obviously decreases in patient on dupilumab. 
This mechanism gives the possibility of protective effect of 
dupilumab in the nature of COVID-19 [62].
Many have proposed that the concept of Th-1/
Th-2 immune balance is very complex and not only 
influenced by the cytokines profile but also by antigen 
presentation, immunogenic and non-immunogenic cells, 
genetic, hormones, oxidative stress, and environment 
[6], [60], [63], [64]. Thus, further research is needed to 
elucidate this matter.
Limitations and Recommendation
One of the limitations of this article is the sparse 
data of COVID-19 due to its novelty. Another limitation 
includes the strength of the data of dupilumab, since 
the most common available sources are randomized-
controlled trials. In addition, most of the sources of the 
immunology cascades are theoretical data, and there is 
still little clinical evidence that can support the theory. 
It is recommended that physicians strictly follow-up 
patients with dupilumab and record their development 
during this pandemic.
The use of biologic modality in dermatological 
conditions during the pandemic may be challenging. 
Any decision either discontinuation or continuation of 
the modality may be obtained based on the evaluation 
of patient’s profile and the risk of contracting COVID-19, 
particularly in high caseload zone. The continuation 
of biologic treatment is highly suggested with careful 
monitoring of any undesirable or uncommon side 
effects. Finally, further studies are required urgently to 
elucidate this matter.
References
1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis 
of coronavirus disease (COVID-19) outbreak. J Autoimmun. 
2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433
 PMid:32113704
2. Kakodkar P, Kaka N, Baig M. A comprehensive literature 
review on the clinical presentation, and management of the 
pandemic coronavirus disease 2019 (COVID-19). Cureus. 
2020;12(4):e7560. https://doi.org/10.7759/cureus.7560
 PMid:32269893
3. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 
“Cytokine Storm’’ in COVID-19. J Infect. 2020;80(6):607-13.
 PMid:32283152
4. Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab 
treatment in moderate-to-severe atopic dermatitis: A systematic 
review and meta-analysis. J Dermatol Sci. 2018;90(2):190-8. 
https://doi.org/10.1016/j.jdermsci.2018.01.016
 PMid:29472119
5. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, 
Rocklin R, et al. Dupilumab treatment in adults with moderate-
to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-9. 
https://doi.org/10.1056/nejmoa1314768
6. Kidd P. Th1/Th2 balance: The hypothesis, its limitations, 
and implications for health and disease. Altern Med Rev. 
2003;8(3):223-46.
 PMid:12946237
7. Balkwill FR. The Cytokine Network. Oxford: Oxford University 
Press; 2000. Available from: https://www.books.google.com.vc/
books?id=8tdCmwEACAAJ. [Last accessed on 2020 Aug 07].
8. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, 
Deleuran M, Fink-Wagner A, et al. Consensus-based European 
guidelines for treatment of atopic eczema (atopic dermatitis) 
in adults and children: Part I. J Eur Acad Dermatol Venereol. 
2018;32(5):657-82. https://doi.org/10.1111/jdv.14891
 PMid:29676534
9. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, 
Weiland SK, et al. Worldwide time trends in the prevalence 
of symptoms of asthma, allergic rhinoconjunctivitis, and 
eczema in childhood: ISAAC Phases One and Three repeat 
multicountry cross-sectional surveys. Lancet (London, 
England). 2006;368(9537):733-43. https://doi.org/10.1016/
s0140-6736(06)69283-0
 PMid:16935684
10. Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy 
Asthma Clin Immunol. 2018;14(2):52. https://doi.org/10.1186/
s13223-018-0281-6
 PMid:30275844
11. Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients 
with atopic dermatitis. Cutis. 2019;104(3):174-7.
 PMid:31675393
12. Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and 
immunomodulator/immunosuppressant use in dermatology. J 
Am Acad Dermatol. 2020;82(5):e173-5.
 PMid:32224277
13. Krakowski AC, Eichenfield LF, Dohil MA. Management of 
atopic dermatitis in the pediatric population. Pediatrics. 
2008;122(4):812-24. https://doi.org/10.1542/peds.2007-2232
 PMid:18829806
14. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, 
Wolff K. Fitzpatrick’s Dermatology in General Medicine. 
8th ed. New York: McGraw-Hill; 2012. p. 165-7. https://doi.
org/10.1111/j.1524-4725.2008.34211.x
15. Boguniewicz M, Fonacier L, Leung DY. Atopic and Contact 
Dermatitis: Clinical Immunology. 5th ed. Netherland: Elsevier 
Ltd.; 2006. p. 611-24.
16. Tada J. Diagnostic standard for atopic dermatitis. JMAJ. 
2002;45(4511):460-5l.
17. Hanifin JM, Rajla G. Diagnostic features of AD. Acta 
Dermatovener (Stockholm). 1980;92:44-7.
AQ5
 Kosasih. The Use of Dupilumab in Atopic Dermatitis During COVID-19
Open Access Maced J Med Sci. 2020 Nov 05; 8(T1):399-407. 405
18. McKenna SP, Doward LC. Quality of life of children with atopic 
dermatitis and their families. Curr Opin Allergy Clin Immunol. 
2008;8(3):228-31.
 PMid:18560297
19. Lifschitz C. The impact of atopic dermatitis on quality of life. Ann 
Nutr Metab. 2015;66(Suppl 1):34-40.
 PMid:25925339
20. Correale CE, Walker C, Murphy L, Craig TJ. Atopic dermatitis: 
A review of diagnosis and treatment. Am Fam Physician. 
1999;60(4):1191-8, 1209-10.
 PMid:10507748
21. Manousaki D, Paternoster L, Standl M, Moffatt MF, Farrall M, 
Bouzigon E, et al. Vitamin D levels and susceptibility to 
asthma, elevated immunoglobulin E levels, and atopic 
dermatitis: A mendelian randomization study. PLoS Med. 
2017;14(5):e1002294. https://doi.org/10.1371/journal.
pmed.1002294
 PMid:28486474
22. Martin MJ, Estravís M, García-Sánchez A, Dávila I, Isidoro-
García M, Sanz C. Genetics and epigenetics of atopic dermatitis: 
An updated systematic review. Genes (Basel). 2020;11(4):442. 
https://doi.org/10.3390/genes11040442
 PMid:32325630
23. Candi E, Schmidt R, Melino G. The cornified envelope: A model 
of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6(4):328-
40. https://doi.org/10.1038/nrm1619
 PMid:15803139
24. Maliyar K, Sibbald C, Pope E, Gary Sibbald R. Diagnosis 
and management of atopic dermatitis: A review. Adv Skin 
Wound Care. 2018;31(12):538-50. https://doi.org/10.1097/01.
asw.0000547414.38888.8d
 PMid:30475283
25. Fujii M. Current understanding of pathophysiological 
mechanisms of atopic dermatitis: Interactions among skin 
barrier dysfunction, immune abnormalities and pruritus. Biol 
Pharm Bull. 2020;43(1):12-9. https://doi.org/10.1248/bpb.
b19-00088
 PMid:31902917
26. Seltmann J, Roesner LM, von Hesler FW, Wittmann M, Werfel T. 
IL-33 impacts on the skin barrier by downregulating the expression 
of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659-61.e4. 
https://doi.org/10.1016/j.jaci.2015.01.048
 PMid:25863977
27. Mayba JN, Gooderham MJ. Review of atopic dermatitis and 
topical therapies. J Cutan Med Surg. 2017;21(3):227-36. https://
doi.org/10.1177/1203475416685077
 PMid:28300440
28. Katayama I, Aihara M, Ohya Y, Saeki H, Shimojo N, Shoji S, 
et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 
2017;66(2):230-47. https://doi.org/10.1016/j.alit.2016.12.003
 PMid:28209325
29. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic 
pruritus in atopic dermatitis: Getting the itch out? Clin Rev 
Allergy Immunol. 2016;51(3):263-92. https://doi.org/10.1007/
s12016-015-8488-5
30. Leung D, Boguniewicz M. Atopic dermatitis and allergic contact 
dermatitis. In: Middleton’s Allergy Essentials. amsterdam: 
Elsevier Inc.; 2017. p. 265-300. https://doi.org/10.1016/
b978-0-323-37579-5.00011-8
31. Rich RR, Fleisher TA, Shearer WT, Schroeder HW Jr., Frew AJ. 
Clinical Immunology: Principles and Practice. 5th ed. Amsterdam, 
Netherlands: Elsevier; 2019.
32. Thaçi D, Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A, 
et al. Efficacy and safety of dupilumab monotherapy in adults 
with moderate-to-severe atopic dermatitis: A pooled analysis 
of two phase 3 randomized trials (LIBERTY AD SOLO 1 and 
LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266-75. 
https://doi.org/10.1016/j.jdermsci.2019.02.002
 PMid:31109652
33. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda 
F, et al. Dupilumab in persistent asthma with elevated eosinophil 
levels. N Engl J Med. 2013;368(26):2455-66. https://doi.
org/10.1056/nejmoa1304048
 PMid:23688323
34. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. 
Epidemiological and clinical characteristics of 99 cases of 2019 
novel coronavirus pneumonia in Wuhan, China: A descriptive 
study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/
s0140-6736(20)30211-7
 PMid:32007143
35. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune 
pathogenesis and diagnosis of COVID-19. J Pharm Anal. 
2020;10(2):102-8.
 PMid:32282863
36. World Health Organization. Timeline of WHO’s response to 
COVID-19. World Health Organ. 2020;1:1-27.
37. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, 
et al. The incubation period of coronavirus disease 2019 (CoVID-
19) from publicly reported confirmed cases: Estimation and 
application. Ann Intern Med. 2020;172(9):577-82. https://doi.
org/10.7326/m20-0504
 PMid:32150748
38. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical 
characteristics of 138 hospitalized patients with 2019 novel 
coronavirus infected pneumonia in Wuhan, China. JAMA. 
2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585
 PMid:32031570
39. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The 
origin, transmission and clinical therapies on coronavirus disease 
2019 (COVID-19) outbreak an update on the status. Mil Med 
Res. 2020;7(1):11. https://doi.org/10.1186/s40779-020-00240-0
40. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: 
A review based on up-to-date knowledge. Am J Otolaryngol. 
2020;41(5):102581. https://doi.org/10.1016/j.amjoto.2020.102581
 PMid:32563019
41. World Health Organization. Report of the WHO-China Joint 
Mission on Coronavirus Disease 2019 (COVID-19). WHO-
China Jt Mission Coronavirus Disease. Geneva: World Health 
Organization; 2019. Available from: https://www.who.int/docs/
default-source/coronaviruse/who-china-joint-mission-on-covid-
19-final-report.pdf. [Last accessed on 2020 Aug 03]. https://doi.
org/10.3410/f.737509210.793572110
42. Morawska L, Tang JW, Bahnfleth W, Bluyssen PM, Boerstra A, 
Buonanno G, et al. How can airborne transmission of COVID-
19 indoors be minimised? Environ Int. 2020;142:105832. https://
doi.org/10.1016/j.envint.2020.105832
 PMid:32521345
43. Setti L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, 
Borelli M, et al. Airborne transmission route of covid-19: Why 
2 meters/6 feet of inter-personal distance could not be enough. 
Int J Environ Res Public Health. 2020;17(8):2932. https://doi.
org/10.3390/ijerph17082932
 PMid:32340347
44. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The 
Digestive System is a Potential Route of 2019-nCov Infection: 
A Bioinformatics Analysis Based on Single-Cell Transcriptomes. 
bioRxiv; 2020. Available from: http://www.biorxiv.org/content/ear
ly/2020/01/31/2020.01.30.927806.abstract. [Last accessed on 
2020 Aug 03]. https://doi.org/10.1101/2020.01.30.927806
45. Xue X, Mi Z, Wang Z, Pang Z, Liu H, Zhang F. High expression 
of ACE2 on keratinocytes reveals skin as a potential target 
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Narrative Review Article
406 https://www.id-press.eu/mjms/index
for SARS-CoV-2. J Invest Dermatol. 2020;1:1-5. https://doi.
org/10.1016/j.jid.2020.05.087
46. Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, et al. Epidemiology, 
genetic recombination, and pathogenesis of coronaviruses. 
Trends Microbiol. 2016;24(6):490-502.
 PMid:27012512
47. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic 
characterisation and epidemiology of 2019 novel coronavirus: 
Implications for virus origins and receptor binding. Lancet. 
2020;395(10224):565-74.
 PMid:32007145
48. Tanonaka K, Marunouchi T. Angiotensin-converting enzyme 
2. Folia Pharmacol Jpn. 2016;147(2):120-1. https://doi.
org/10.1254/fpj.147.120
49. Perlman S, Netland J. Coronaviruses post-SARS: Update on 
replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439-
50. https://doi.org/10.1038/nrmicro2147
 PMid:19430490
50. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, 
Meyerholz DK, et al. Dysregulated Type I interferon and 
inflammatory monocyte-macrophage responses cause lethal 
pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 
2016;19(2):181-93. https://doi.org/10.1016/j.chom.2016.01.007
 PMid:26867177
51. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical 
features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.
org/10.1016/s0140-6736(20)30183-5
52. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 
2019 (COVID-19): Current status and future perspectives. 
Int J Antimicrob Agents. 2020;55(5):105951. https://doi.
org/10.1016/j.ijantimicag.2020.105951
 PMid:32234466
53. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical 
and immunological features of severe and moderate coronavirus 
disease 2019. J Clin Invest. 2020;130(5):2620-9.
 PMid:32217835
54. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility 
of clinical laboratory data determinations for patients with the 
severe COVID-19. J Med Virol. 2020;92(7):791-6. https://doi.
org/10.1002/jmv.25770
 PMid:32181911
55. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of 
mortality due to COVID-19 based on an analysis of data of 150 
patients from Wuhan, China. Intensive Care Med. 2020;46:846-
8. https://doi.org/10.1007/s00134-020-05991-x
 PMid:32125452
56. Patruno C, Nisticò SP, Fabbrocini G, Napolitano M. 
COVID-19, quarantine, and atopic dermatitis. Med 
Hypotheses. 2020;143(1):109852. https://doi.org/10.1016/j.
mehy.2020.109852
 PMid:32447099
57. Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T, 
et al. European Task Force on Atopic Dermatitis statement 
on severe acute respiratory syndrome coronavirus 2 (SARS-
Cov-2) infection and atopic dermatitis. J Eur Acad Dermatology 
Venereol. 2020;34(6):e241-2. https://doi.org/10.1111/jdv.16411
 PMid:32223003
58. Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. 
Safety of dupilumab in atopic patients during COVID-19 
outbreak. J Dermatolog Treat. 2020;1:1-2. https://doi.org/10.10
80/09546634.2020.1771257
59. Georgakopoulos JR, Yeung J. Patient-driven discontinuation 
of dupilumab during the COVID-19 pandemic in two academic 
hospital clinics at the University of Toronto. J Cutan Med Surg. 
2020;1:1-2. https://doi.org/10.1177/1203475420930223
60. Lafaille JJ. The role of helper T cell subsets in autoimmune 
diseases. Cytokine Growth Factor Rev. 1998;9(2):139-51. 
https://doi.org/10.1016/s1359-6101(98)00009-4
 PMid:9754708
61. Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, 
Kostic A, et al. Dupilumab improves the molecular signature 
in skin of patients with moderate-to-severe atopic dermatitis. 
J Allergy Clin Immunol. 2014;134(6):1293-300. https://doi.
org/10.1016/j.jaci.2014.10.013
 PMid:25482871
62. Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. 
Dupilumab and COVID-19: What should we expect? Dermatol 
Ther. 2020;33(4):13502. https://doi.org/10.1111/dth.13502
63. Nicolson KS, Streeter HB, Verhagen J, Sabatos-peyton CA, 
Morgan DJ, Wraith DC. Negative feedback control of the 
autoimmune response through antigen-induced differentiation 
of IL-10-secreting Th1 cells. J Exp Med. 2009;206(8):1755-67. 
https://doi.org/10.1084/jem.20082118
 PMid:19635862
64. Fowler DH. Th1/Th2 and Tc1/Tc2 cells: Experimental 
models and clinical translation. J Allergy Clin Immunol. 
2001;107(2):337-44.
Author Queries???
AQ5: Kindly move reference citation 1-7 to text part.
 Kosasih. The Use of Dupilumab in Atopic Dermatitis During COVID-19
Open Access Maced J Med Sci. 2020 Nov 05; 8(T1):399-407. 407
Appendix
Appendix 1: SCORAD. Adapted from. Honari G. (2017) Clinical Scoring of Atopic Dermatitis. In: Humbert P., Fanian F., Maibach H., Agache P. 
(eds) Agache’s Measuring the Skin. Springer, Cham. https://doi.org/10.1007/978-3-319-32383-1_94
